NCT06847191

NE3107 in Adults With Neurological Symptoms of Long COVID

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults With Long COVID

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 208 (estimated)
• Sponsor: BioVie Inc. · Industry
• Sex: All
• Age: 18 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call

Conditions

• Long COVID

Interventions

Type	Name	Description
DRUG	NE3107	20 mg Capsule
DRUG	Placebo	placebo capsule

Timeline

• Start date: 2025-04-29
• Primary completion: 2026-06-01
• Completion: 2026-08-01
• First posted: 2025-02-26
• Last updated: 2026-02-19

Locations

20 sites across 1 country: United States

Regulatory

• FDA-regulated drug study